Predicting Sensitivity to Breast Cancer Therapy

We combined the individual predictions into a testing algorithm for predicted sensitivity to adjuvant treatment of HER2-negative breast cancer with taxane-anthracycline chemotherapy: 1) sensitivity to endocrine therapy assessed based on an independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index)^{21 (link)}; 2) resistance to chemotherapy predicted either by early distant relapse events or by extensive residual disease after neoadjuvant chemotherapy; and 3) sensitivity (pathologic response) to chemotherapy (Figure 1). Additional methodological details are provided in the Supplemental Appendix.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Martin M., Cotrina J., Gomez H., Hubbard R., Chacón J.I., Ferrer-Lozano J., Dyer R., Buxton M., Gong Y., Wu Y., Ibrahim N., Andreopoulou E., Ueno N.T., Hunt K., Yang W., Nazario A., DeMichele A., O’Shaughnessy J., Hortobagyi G.N, & Symmans W.F. (2011). GENOMIC PREDICTOR OF RESPONSE AND SURVIVAL FOLLOWING TAXANE-ANTHRACYCLINE CHEMOTHERAPY FOR INVASIVE BREAST CANCER. JAMA, 305(18), 1873-1881.

Publication 2011

Adjuvant Anthracycline Cancer of breast Chemotherapy Endocrine Gene Her2 Neoadjuvant chemotherapy Relapse Residual disease Sensitivity Taxane Therapy

Corresponding Organization : Nuvera Biosciences (United States)

Top 5 similar protocols

Protocol cited in 57 other protocols

Variable analysis

independent variables

Sensitivity to endocrine therapy assessed based on an independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index)
Resistance to chemotherapy predicted either by early distant relapse events or by extensive residual disease after neoadjuvant chemotherapy
Sensitivity (pathologic response) to chemotherapy

dependent variables

Outcome of adjuvant treatment of HER2-negative breast cancer with taxane-anthracycline chemotherapy

control variables

Independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index)
Early distant relapse events or extensive residual disease after neoadjuvant chemotherapy
Pathologic response to chemotherapy

controls

Independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index) as a positive control
Early distant relapse events or extensive residual disease after neoadjuvant chemotherapy as a negative control
Pathologic response to chemotherapy as a positive control

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!